<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03200574</url>
  </required_header>
  <id_info>
    <org_study_id>APR002</org_study_id>
    <nct_id>NCT03200574</nct_id>
  </id_info>
  <brief_title>Behavior of Valve Leaflets</brief_title>
  <acronym>BELIEVE</acronym>
  <official_title>Behavior of Valve Leaflets and the Incidence of Reduced Mobility Post-surgical Aortic Valve Implant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LivaNova</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LivaNova</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, interventional, multi-center trial to report the overall incidence of
      reduced leaflet motion identified by CT imaging in patients receiving a commercially approved
      LivaNova bioprosthetic aortic heart valve up to 1 year post implant.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, interventional, multi-center trial to report the overall incidence of
      reduced leaflet motion identified by CT imaging in patients receiving a commercially approved
      LivaNova bioprosthetic aortic heart valve up to 1 year post implant, on patients that are off
      anticoagulation for at least 30 days. A minimum of 200 subjects with evaluable 4D CT scans
      will be enrolled at approximately 15 investigational sites where the devices are commercially
      available. For asymptomatic subjects, PIs and subjects will be blinded from the CT imaging
      results and from the Core Lab findings.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 6, 2017</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Prospective, multi-center trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in leaflet motion</measure>
    <time_frame>1 year post-implant</time_frame>
    <description>Report the overall incidence of reduced leaflet motion identified by CT imaging in commercially approved LivaNova bioprosthetic aortic heart valves up to 1 year post implant on patients that are off anticoagulation for at least 30 days.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Leaflet motion in symptomatic and asymptomatic subjects outcomes</measure>
    <time_frame>up to 1 year post-implant</time_frame>
    <description>Incidence of reduced leaflet motion in symptomatic and asymptomatic subjects based on CT outcomes and anticoagulation and dual antiplatelet treatment modalities up to 1 year post-implant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduced leaflet motion through 4D volume-rendered CT scan</measure>
    <time_frame>up to 1 year post-implant</time_frame>
    <description>Incidence of reduced leaflet motion through 4D volume-rendered CT scan with contrast up to 1 year post-implant, in subjects in which reduced leaflet motion was previously detected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in leaflet motion by relationship to devices, procedure, or other causes</measure>
    <time_frame>up to 1 year post-implant</time_frame>
    <description>Incidence of reduced leaflet motion considering relationship to the devices, procedure, or other causes up to 1 year post-implant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from all-cause mortality</measure>
    <time_frame>up to 1 year post-implant</time_frame>
    <description>Survival data will be evaluated using Kaplan-Meier method. The degree of uncertainty will be expressed with 95% confidence limits calculated per the method proposed by Greenwood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from valve re-intervention</measure>
    <time_frame>up to 1 year post-implant</time_frame>
    <description>Survival data will be evaluated using Kaplan-Meier method. The degree of uncertainty will be expressed with 95% confidence limits calculated per the method proposed by Greenwood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from myocardial infarction</measure>
    <time_frame>up to 1 year post-implant</time_frame>
    <description>Survival data will be evaluated using Kaplan-Meier method. The degree of uncertainty will be expressed with 95% confidence limits calculated per the method proposed by Greenwood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from structural valve deterioration</measure>
    <time_frame>up to 1 year post-implant</time_frame>
    <description>Survival data will be evaluated using Kaplan-Meier method. The degree of uncertainty will be expressed with 95% confidence limits calculated per the method proposed by Greenwood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from moderate or severe valve regurgitation</measure>
    <time_frame>up to 1 year post-implant</time_frame>
    <description>Survival data will be evaluated using Kaplan-Meier method. The degree of uncertainty will be expressed with 95% confidence limits calculated per the method proposed by Greenwood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from valve endocarditis</measure>
    <time_frame>up to 1 year post-implant</time_frame>
    <description>Survival data will be evaluated using Kaplan-Meier method. The degree of uncertainty will be expressed with 95% confidence limits calculated per the method proposed by Greenwood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from valve thrombosis</measure>
    <time_frame>up to 1 year post-implant</time_frame>
    <description>Survival data will be evaluated using Kaplan-Meier method. The degree of uncertainty will be expressed with 95% confidence limits calculated per the method proposed by Greenwood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from thromboembolic events</measure>
    <time_frame>up to 1 year post-implant</time_frame>
    <description>Survival data will be evaluated using Kaplan-Meier method. The degree of uncertainty will be expressed with 95% confidence limits calculated per the method proposed by Greenwood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from hemolysis</measure>
    <time_frame>up to 1 year post-implant</time_frame>
    <description>Survival data will be evaluated using Kaplan-Meier method. The degree of uncertainty will be expressed with 95% confidence limits calculated per the method proposed by Greenwood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from major bleeding</measure>
    <time_frame>up to 1 year post-implant</time_frame>
    <description>Survival data will be evaluated using Kaplan-Meier method. The degree of uncertainty will be expressed with 95% confidence limits calculated per the method proposed by Greenwood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New York Heart Association (NYHA) Assessment</measure>
    <time_frame>1 year post-implant</time_frame>
    <description>NYHA assessment at 1 year post-implant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aortic Peak Gradient through transthoracic echocardiogram (TTE)</measure>
    <time_frame>up to 1 year post-implant</time_frame>
    <description>Summary statistics (means, Standard Deviation, median, quartiles and range values for continuous variables; count and frequency distributions for categorical variables) of Hemodynamic assessment up to 1 year post-implant through Echocardiographic Core Lab transthoracic echocardiogram (TTE)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aortic Mean Gradient through transthoracic echocardiogram (TTE)</measure>
    <time_frame>up to 1 year post-implant</time_frame>
    <description>Summary statistics (means, Standard Deviation, median, quartiles and range values for continuous variables; count and frequency distributions for categorical variables) of Hemodynamic assessment up to 1 year post-implant through Echocardiographic Core Lab transthoracic echocardiogram (TTE)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Doppler Velocity Index through transthoracic echocardiogram (TTE)</measure>
    <time_frame>up to 1 year post-implant</time_frame>
    <description>Summary statistics (means, Standard Deviation, median, quartiles and range values for continuous variables; count and frequency distributions for categorical variables) of Hemodynamic assessment up to 1 year post-implant through Echocardiographic Core Lab transthoracic echocardiogram (TTE)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effective Orifice Area through transthoracic echocardiogram (TTE)</measure>
    <time_frame>up to 1 year post-implant</time_frame>
    <description>Summary statistics (means, Standard Deviation, median, quartiles and range values for continuous variables; count and frequency distributions for categorical variables) of Hemodynamic assessment up to 1 year post-implant through Echocardiographic Core Lab transthoracic echocardiogram (TTE)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Aortic Regurgitation through transthoracic echocardiogram (TTE)</measure>
    <time_frame>up to 1 year post-implant</time_frame>
    <description>Summary statistics (means, Standard Deviation, median, quartiles and range values for continuous variables; count and frequency distributions for categorical variables) of Hemodynamic assessment up to 1 year post-implant through Echocardiographic Core Lab transthoracic echocardiogram (TTE)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Central Aortic Regurgitation through transthoracic echocardiogram (TTE)</measure>
    <time_frame>up to 1 year post-implant</time_frame>
    <description>Summary statistics (means, Standard Deviation, median, quartiles and range values for continuous variables; count and frequency distributions for categorical variables) of Hemodynamic assessment up to 1 year post-implant through Echocardiographic Core Lab transthoracic echocardiogram (TTE)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Paravalvular Aortic Regurgitation through transthoracic echocardiogram (TTE)</measure>
    <time_frame>up to 1 year post-implant</time_frame>
    <description>Summary statistics (means, Standard Deviation, median, quartiles and range values for continuous variables; count and frequency distributions for categorical variables) of Hemodynamic assessment up to 1 year post-implant through Echocardiographic Core Lab transthoracic echocardiogram (TTE)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">230</enrollment>
  <condition>Aortic-valve Replacement</condition>
  <arm_group>
    <arm_group_label>Aortic Valve</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>LivaNova bioprosthetic aortic heart valve replacement</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>4D Cardiac CT Scan</intervention_name>
    <description>4D CT scan obtained at minimum of 1 month after the discontinuation of the anticoagulation or dual antiplatelet therapy</description>
    <arm_group_label>Aortic Valve</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>LivaNova Bioprothetic Aortic Valve Implant</intervention_name>
    <description>Study includes patients that have received a commercially approved LivaNova bioprosthetic aortic heart valve (Perceval, Crown PRT, Solo Smart) as standard of care.</description>
    <arm_group_label>Aortic Valve</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The subject has been successfully implanted with a commercially approved LivaNova
             bioprosthetic valve according to the instructions for use (IFU)

          2. The subject has signed the informed consent.

          3. The subject is at least 18 years of age at the time of implant and consent signature

          4. The subject will be available for post-operative follow-up through one year

        Exclusion Criteria:

          1. The subject has a planned concomitant cardiac procedure other than coronary artery
             bypass graft (CABG) and septal myectomy, including MAZE procedures, atrial
             fibrillation surgery, and left atrial appendage exclusion or resection, or has a
             prosthetic heart valve or annuloplasty ring in any position

          2. The subject has any medical condition requiring long term (&gt; 6 months) anticoagulation
             or dual antiplatelet therapy

          3. The subject has any clinical condition precluding the use of CT imaging with contrast

          4. The subject had a stroke or myocardial infarction (STEMI and NSTEMI) within 30 days of
             the planned valve implant surgery

          5. The subject has active endocarditis, myocarditis, or sepsis

          6. The subject is in cardiogenic shock manifested by low cardiac output and needing
             hemodynamic support

          7. The subject is already included in another clinical trial that could confound the
             results of this clinical investigation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Niv Ad, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington Adventist Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Federico Asch, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medstar Health Research Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laura Yates</last_name>
    <phone>281-228-7433</phone>
    <email>lyates@livanova.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>St. Vincent Cardiovascular Research Institute</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46290</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jana Fisher, BSN</last_name>
      <phone>317-583-7818</phone>
      <email>jana.fisher@ascension.org</email>
    </contact>
    <investigator>
      <last_name>David Heimansohn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington Adventist Hospital</name>
      <address>
        <city>Takoma Park</city>
        <state>Maryland</state>
        <zip>20912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tamika McGee</last_name>
      <phone>301-891-5493</phone>
      <email>tmagee@adventisthealthcare.com</email>
    </contact>
    <investigator>
      <last_name>Niv Ad, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oakwood Hospital</name>
      <address>
        <city>Dearborn</city>
        <state>Michigan</state>
        <zip>48124</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tammy Osentoski, BSN</last_name>
      <phone>248-551-9866</phone>
      <email>tammy.osentoski@beaumont.org</email>
    </contact>
    <investigator>
      <last_name>Reza Dabir, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deborah Rolbiecki, CRC</last_name>
      <phone>507-255-5027</phone>
      <email>rolbiecki.deborah@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Sameh Said, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Valley Health</name>
      <address>
        <city>Winchester</city>
        <state>Virginia</state>
        <zip>22601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashley Zelaski, BSN</last_name>
      <phone>540-536-7542</phone>
      <email>azelaski@valleyhealthlink.com</email>
    </contact>
    <investigator>
      <last_name>Basel Ramlawi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Adams DH, Popma JJ, Reardon MJ. Transcatheter aortic-valve replacement with a self-expanding prosthesis. N Engl J Med. 2014 Sep 4;371(10):967-8. doi: 10.1056/NEJMc1408396.</citation>
    <PMID>25184874</PMID>
  </reference>
  <reference>
    <citation>Leon MB, Smith CR, Mack M, Miller DC, Moses JW, Svensson LG, Tuzcu EM, Webb JG, Fontana GP, Makkar RR, Brown DL, Block PC, Guyton RA, Pichard AD, Bavaria JE, Herrmann HC, Douglas PS, Petersen JL, Akin JJ, Anderson WN, Wang D, Pocock S; PARTNER Trial Investigators. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med. 2010 Oct 21;363(17):1597-607. doi: 10.1056/NEJMoa1008232. Epub 2010 Sep 22.</citation>
    <PMID>20961243</PMID>
  </reference>
  <reference>
    <citation>Mohr FW, Holzhey D, Möllmann H, Beckmann A, Veit C, Figulla HR, Cremer J, Kuck KH, Lange R, Zahn R, Sack S, Schuler G, Walther T, Beyersdorf F, Böhm M, Heusch G, Funkat AK, Meinertz T, Neumann T, Papoutsis K, Schneider S, Welz A, Hamm CW; GARY Executive Board. The German Aortic Valve Registry: 1-year results from 13,680 patients with aortic valve disease. Eur J Cardiothorac Surg. 2014 Nov;46(5):808-16. doi: 10.1093/ejcts/ezu290. Epub 2014 Jul 30.</citation>
    <PMID>25079769</PMID>
  </reference>
  <reference>
    <citation>Laschinger JC, Wu C, Ibrahim NG, Shuren JE. Reduced Leaflet Motion in Bioprosthetic Aortic Valves--The FDA Perspective. N Engl J Med. 2015 Nov 19;373(21):1996-8. doi: 10.1056/NEJMp1512264. Epub 2015 Oct 5.</citation>
    <PMID>26437127</PMID>
  </reference>
  <reference>
    <citation>Makkar RR, Fontana G, Jilaihawi H, Chakravarty T, Kofoed KF, De Backer O, Asch FM, Ruiz CE, Olsen NT, Trento A, Friedman J, Berman D, Cheng W, Kashif M, Jelnin V, Kliger CA, Guo H, Pichard AD, Weissman NJ, Kapadia S, Manasse E, Bhatt DL, Leon MB, Søndergaard L. Possible Subclinical Leaflet Thrombosis in Bioprosthetic Aortic Valves. N Engl J Med. 2015 Nov 19;373(21):2015-24. doi: 10.1056/NEJMoa1509233. Epub 2015 Oct 5.</citation>
    <PMID>26436963</PMID>
  </reference>
  <reference>
    <citation>Beholz S, Repossini A, Livi U, Schepens M, El Gabry M, Matschke K, Trivedi U, Eckel L, Dapunt O, Zamorano JL. The Freedom SOLO valve for aortic valve replacement: clinical and hemodynamic results from a prospective multicenter trial. J Heart Valve Dis. 2010 Jan;19(1):115-23.</citation>
    <PMID>20329497</PMID>
  </reference>
  <reference>
    <citation>Thalmann M, Grubitzsch H, Matschke K, Glauber M, Tan E, Francois K, Amorim MJ, Hensens AG, Cesari F, Feyrer R, Diegeler A, Veit F, Repossini A; Freedom Solo Investigators. A European Multicenter Study of 616 Patients Receiving the Freedom Solo Stentless Bioprosthesis. Ann Thorac Surg. 2016 Jan;101(1):100-8. doi: 10.1016/j.athoracsur.2015.06.096. Epub 2015 Oct 9.</citation>
    <PMID>26443880</PMID>
  </reference>
  <reference>
    <citation>Grubitzsch H, Wang S, Matschke K, Glauber M, Heimansohn D, Tan E, Francois K, Thalmann M. Clinical and haemodynamic outcomes in 804 patients receiving the Freedom SOLO stentless aortic valve: results from an international prospective multicentre study. Eur J Cardiothorac Surg. 2015 Mar;47(3):e97-104. doi: 10.1093/ejcts/ezu471. Epub 2014 Dec 13.</citation>
    <PMID>25501554</PMID>
  </reference>
  <reference>
    <citation>Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP 3rd, Guyton RA, O'Gara PT, Ruiz CE, Skubas NJ, Sorajja P, Sundt TM 3rd, Thomas JD; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014 Jun 10;63(22):e57-185. doi: 10.1016/j.jacc.2014.02.536. Epub 2014 Mar 3. Erratum in: J Am Coll Cardiol. 2014 Jun 10;63(22):2489. Dosage error in article text.</citation>
    <PMID>24603191</PMID>
  </reference>
  <reference>
    <citation>Smith CR, Leon MB, Mack MJ, Miller DC, Moses JW, Svensson LG, Tuzcu EM, Webb JG, Fontana GP, Makkar RR, Williams M, Dewey T, Kapadia S, Babaliaros V, Thourani VH, Corso P, Pichard AD, Bavaria JE, Herrmann HC, Akin JJ, Anderson WN, Wang D, Pocock SJ; PARTNER Trial Investigators. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med. 2011 Jun 9;364(23):2187-98. doi: 10.1056/NEJMoa1103510. Epub 2011 Jun 5.</citation>
    <PMID>21639811</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 9, 2017</study_first_submitted>
  <study_first_submitted_qc>June 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 27, 2017</study_first_posted>
  <last_update_submitted>April 9, 2018</last_update_submitted>
  <last_update_submitted_qc>April 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Perceval</keyword>
  <keyword>Mitroflow</keyword>
  <keyword>CROWN PRT</keyword>
  <keyword>Freedom Solo</keyword>
  <keyword>Solo Smart</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

